Ranjit Nair, MD

Peer-Reviewed Articles

1. Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy. Int J Radiat Oncol Biol Phys None(None):None, 2024. PMID: 39303997.
2. Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez MA, Lee HJ, Wang M, Flowers C, Feng L, Esmaeli B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 10(9):1195-1203, 2024. PMID: 38990564.
3. Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol 11(9):e671-e681, 2024. PMID: 39067464.
4. Gurumurthi, A, Chin, CK, Feng, L, Fowler, N, Strati, P, Hagemeister, FB, Fayad, LE, Westin, JR, Obi, C, Arafat, J, Nair, R, Steiner, RE, Neelapu, SS, Flowers, CR, Nastoupil, L. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma. EClinicalMedicine 74, 2024. PMID: 39161543.
5. Gurumurthi A, Chin CK, Feng L, Fowler NH, Strati P, Hagemeister FB, Fayad LE, Westin JR, Obi C, Arafat J, Nair R, Steiner RE, Neelapu SS, Flowers CR, Nastoupil LJ. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial. EClinicalMedicine 74(None):102747, 2024. PMID: 39161543.
6. Wu SY, Damron EP, Xu J, Fang PQ, Dai J, Nair R, Malpica Castillo LE, Fayad LE, Torres-Cabala CA, Medeiros LJ, Vega F, Miranda RN, Duvic M, Pinnix CC, Dabaja BS, Iyer SP, Huen AO, Gunther JR. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol None(None):None, 2024. PMID: 38955474.
7. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. PMID: 38843856.
8. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. PMID: 38031807.
9. Ruan W, Li T, Lee J, Bang IH, Deng W, Ma X, Yoo SH, Kim B, Li J, Yuan X, An YA, Wang YY, Liang Y, Deberge M, Zhang D, Zhou Z, Wang Y, Gorham J, Seidman JG, Seidman CE, Aranki SF, Nair R, Li L, Narula J, Zhao Z, Abebe AG, Muehlschlegel JD, Tsai KL, Eltzschig HK. The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injury. Res Sq None(None):None, 2024. PMID: 38464103.
10. Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 14(None):1447020, 2024. PMID: 39324011.
11. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David KA, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel SH, Torka P, Lynch RC, Smith SD, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang PQ, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of Cumulative Dose of Brentuximab Vedotin on Outcomes of Frontline Therapy for Advanced Stage Hodgkin Lymphoma. Blood Adv 7(24):7485-7493, 2023. e-Pub 2023. PMID: 37603594.
12. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
13. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
14. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
15. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2022. PMID: 35952327.
16. Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, Castillo LEM, Nair R, Steiner RE, Strati P, Huen AO, Iyer SP, Pinnix CC, Dabaja BS, Gunther JR. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Adv Radiat Oncol 8(6):101279, 2023. e-Pub 2023. PMID: 37448588.
17. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2022. PMID: 36068929.
18. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
19. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. PMID: 36384092.
20. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
21. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
22. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
23. Shbib Dabaja B, Boyce-Fappiano D, Dong W, Damron E, Fang P, Gunther J, Rodriguez MA, Strati P, Steiner R, Nair R, Lee H, Abou Yehia Z, Shihadeh F, Pinnix C, Ng AK. Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experience. Clin Transl Radiat Oncol 35:64-69, 2022. e-Pub 2022. PMID: 35601797.
24. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
25. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
26. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
27. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):74-83, 2022. e-Pub 2021. PMID: 34435552.
28. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
29. Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11(9):153, 2021. e-Pub 2021. PMID: 34531377.
30. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. PMID: 34264268.
31. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
32. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
33. Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
34. Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients. Blood 137(18):2558-2562, 2021. e-Pub 2020. PMID: 33512386.
35. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
36. Nair R, Drillet G, Lhomme F, Le Bras A, Michel L, Rossi J, Sherman M, Xue A, Kerber A, Jittapiromsak N, Chi L, Tummala S, Neelapu SS, Houot R. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 106(5):1504-1506, 2021. e-Pub 2021. PMID: 32732365.
37. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 109(5):1414-1420, 2021. e-Pub 2020. PMID: 33309978.
38. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open 3(9):E2013935, 2020. e-Pub 2020. PMID: 32990738.
39. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. PMID: 32822484.
40. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
41. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. PMID: 32645136.
42. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. PMID: 32589728.
43. Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem 1(1):272-276, 2020. e-Pub 2020. PMID: 32864660.
44. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
45. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
46. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1380-1387, 2020. e-Pub 2020. PMID: 31971032.
47. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
48. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Ju Lee H, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma 61(1):1-5, 2020. e-Pub 2019. PMID: 31373240.
49. Tabchi, S, Nair, R, Kunacheewa, C, Patel, K, Lee, HC, Thomas, SK, Amini, B, Ahmed, S, Mehta, RS, Bashir, Q, Qazilbash, MH, Weber, DM, Orlowski, R, Alexanian, R, Feng, L, Manasanch, EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia 19(9):560-569, 2019. PMID: 31201134.
50. Tolay S, Nair R, McIntosh AF, Sopka DM, Nair SG. Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation. Oncologist 24(1):e49-e52, 2019. e-Pub 2018. PMID: 30104290.
51. Nair R, Tabchi S, Hagemeister F. Obinutuzumab Treatment of Follicular Lymphoma. N Engl J Med 377(26):2605, 2017. PMID: 29281573.
52. Sreedhar A, Feden D, Perilli G, Nair R, Magaji V. 48, XXYY Genotype: Case Report of a Rare Clinical Syndrome. Journal of Endocrinology and Diabetes 2(None):1-3, 2016. PMID: None.
53. Nair R, Mishriki YY. Giant Hiatal Hernia Mimicking Cardiac Tamponade. A Focus on Cardiology 53(9):None, 2013. PMID: None.

Invited Articles

1. R Nair R, K Patel K. Emerging role of CAR T cell therapy in Multiple Myeloma. Advances in Cell and Gene Therapy None(None):None, 2018. PMID: None.

Other Articles

1. Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Cai Q, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 15(1):8668, 2024. PMID: 39375332.
2. Briete LD, Towers WF, Bone R, Nair R, Steck M, Cutshall BT, Shah SP Perioperative Anticoagulation Management. Crit Care Nurs Q 45(2):119-131, 2022. PMID: 35212652.
3. Duke TC, Nair R, Torres-Cabala C, Amaria RN, Keiser E, Miranda R, Iyer SP, Heberton M Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Rep 6(12):1264-1267, 2020. PMID: 33294560.
4. Nair R, Neelapu SS The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31(3):293-298, 2018. PMID: 30213399.
5. Sreedhar A, Nair R, Scialla W Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst. Anticancer Res 38(1):509-512, 2018. PMID: 29277816.
6. Nair R, Shah U Lactic Acidosis: A Rare Oncological Emergency in Solid Tumors at Presentation. Am J Med Sci 353(4):402-406, 2017. PMID: 28317631.
7. Nair R, Gheith S Flame cell in IgA monoclonal gammopathy of undetermined significance. Blood 129(10):1402, 2017. PMID: 28280047.
8. Sreedhar A, Sheikh HA, Scagliotti CJ, Nair R Advanced-stage calciphylaxis: Think before you punch. Cleve Clin J Med 83(8):562-4, 2016. PMID: 27505874.
9. Nair R, Gheith S, Lamparella N Rituximab-Induced Splenic Rupture and Cytokine Release. Am J Case Rep 17:165-9, 2016. PMID: 26972227.
10. Nair R, Gheith S, Nair SG Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. N Engl J Med 374(11):1096-7, 2016. PMID: 26981948.
11. Nair R, Mishriki YY Miss the ear, and you may miss the diagnosis. Cleveland Clinic Journal of Medicine 81(11):656-7, 2014. PMID: 25368214.
12. Nair R, Gheith S, Popescu D, Agostino NM A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide. International Journal of Clinical Experimental Pathology 7(5):2683-9, 2014. PMID: 24966987.
13. Nair, R, Mishriki, YY A focus on cardiology. Consultant 53(9), 2013. PMID: None.

Abstracts

1. Strati P, Feng L, Westin J, Nair R, Fayad L, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Marques-Piubelli ML, Turova P, Zaitsev A, Wang I, Flowers CR, Nastoupil LJ, Neelapu SS. Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study. Blood 142(1):983, 2023. PMID: None.
2. Gunther J, Xu J, Bhutani MS, Strati P, Fang P, Wu S, Dabaja BS, Dong W, Bhosale P, Flowers CR, Nair R, Malpica L, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma. Blood 142(1):298, 2023. PMID: None.
3. Elias A, Marques-Piubelli ML, Nair R, Prakash R, Ahmed S, Malpica L, Lee HJ, Xu J, Flowers CR, Neelapu SS, Vega F, Miranda R, Iyer SP. Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma. Blood 142(1):1714, 2023. PMID: None.
4. McCurry D, Westin J, Feng L, Ahmed S, Nair R, Steiner RE, Wynn L, Thomas J, Dsouza LH, Samaniego F, Neelapu SS, Nastoupil LJ. Phase 1 Dose Escalation Study of Pembrolizumab in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Large B-Cell or Follicular Lymphoma Following Progression after Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood 142(1):4466, 2023. PMID: None.
5. Westin J, Nair R, Fayad L, Iyer SP, Malpica L, Neelapu SS, Samaniego F, Steiner RE, Strati P, Mathew S, Griffith D, Nastoupil LJ, Montinez W, Rodriguez MA, Hagemeister F, Feng L, Vega F, Flowers CR, Ahmed S. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma. Blood 142(1):1721, 2023. PMID: None.
6. Westin J, Steiner RE, Chihara D, Ahmed S, Jain P, Malpica L, Iyer SP, Fayad L, Nair R, Nastoupil LJ, Neelapu SS, Henderson J, Rodriguez MA, Hagemeister F, Vega F, Pulsifer B, Tom J, Durmic I, Masand G, Feng L, Green MR, Flowers CR, Strati P. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Di. Blood 142(1):856, 2023. PMID: None.
7. Zaki AA, Feng L, Westin J, Nair R, Fayad L, Watson G, Adkins S, Shpall EJ, Marques-Piubelli ML, Henderson J, Nastoupil LJ, Flowers CR, Ahmed S, Neelapu SS, Strati P. A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy. Blood 142(1):3098, 2023. PMID: None.
8. Jain P, Lee HJ, Westin J, Nastoupil LJ, Fayad L, Nair R, Iyer SP, Kanagal-Shamanna R, Fetooh A, Hill HA, Ok CY, Chen W, Oriabure O, Feng L, Tang G, Vega F, Badillo M, Flowers CR, Wang ML. Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. Blood 142(1):1688, 2023. PMID: None.
9. Jain P, Chi Young OK, Nastoupil LJ, Westin J, Hill HA, Nair R, Iyer SP, Fetooh A, Lee HJ, Ahmed S, Kanagal-Shamanna R, Jelloul FZ, Malpica Castillo LE, Liu Y, Li Y, Vargas J, Feng L, Badillo M, Thirumurthi S, Xu G, Deswal A, Iliescu C, Nguyen VQ, Tang G, Patel KP, Vega F, Medeiros L, Wang ML, Flowers CR. Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial. Blood 142(1):3036, 2023. PMID: None.
10. Gaballa S, Nair R, Jacobs RW, Devata S, Cho S, Stevens DA, Yoon DH, Shah NN, Brennan D, Law J, Chen R, Sermer D, Lesley R, Buelow B, Forcina A, Hou J. Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial. Blood 142(1):1662, 2023. PMID: None.
11. Lionel A, Long J, Prakash R, Edelkamp P, Knafl M, Ahmed S, Strati P, Nair R, Chien KS, Chihara D, Westin J, Khawaja F, Nastoupil LJ, Manzano J, Mulanovich V, Team D, Daver N, Futreal A, Woodman SE, Flowers CR, Neelapu SS, Iyer SP. Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies. Blood 142(1):3507, 2023. PMID: None.
12. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Liu Y, Hill HA, Li Y, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Siddiqui A, Xu G, Deswal A, Iliescu C, Badillo M, Li S, Ky M, Avellaneda M, Tang G, Vega F, Flowers CR, Wang ML. Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma. Blood 142(1):3034, 2023. PMID: None.
13. Nair R, Ogundipe I, Gunther J, Medeiros L, Jain P, Nastoupil LJ, Pinnix CC, Malpica L, Ahmed S, Miranda R, Fayad L, Steiner RE, Hagemeister F, Lee HJ, Rodriguez MA, Strati P, Chihara D, Wang M, Nieto Y, Ramdial J, Zaki AA, Nze C, Green MR, Dabaja BS, Xu J, Thakral B, Neelapu SS, Vega F, Flowers CR, Fang P, Westin J, Feng L, Iyer SP. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience. Blood 142(1):6327, 2023. PMID: None.
14. Steiner RE, Strati P, Flowers CR, Neelapu SS, Green MR, Nastoupil L, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Blood 138(None):1408, 2021. PMID: None.
15. Al Zaki A, Westin JR, Watson G, Feng L, Ahmed S, Mistry H, Nastoupil L, Hawkins M, Nair R, Iyer SP, Lee H. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. Blood 138(None):3870, 2021. PMID: None.
16. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Cabala CT, Heberton M, Fang P, Ahmed S, Miranda RN. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood 138(None):4536, 2021. PMID: None.
17. Cherng HJ, Sun R, Yang H, Deng Q, Fayad L, Fowler NH, Parmar S, Nair R, Ahmed S, Steiner RE, Hagemeister FB, Lee HJ. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Blood 138(None):38, 2021. PMID: None.
18. Westin JR, Steiner R, Feng L, Strati P, Flowers CR, Neelapu SS, Nastoupil L, Chihara D, Hagemeister FB, Ahmed S, Nair R. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. Blood 138(None):3572, 2021. PMID: None.
19. Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, Chihara D, Steiner R, Fayad L, Samaniego F, Ahmed S. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood 138:2463, 2021. PMID: None.
20. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P. Outcome of Patients with T-Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood 138(None):1448, 2021. PMID: None.
21. Wu SY, Fang P, Huen AO, Iyer SP, Nair R, Steiner R, Castillo LM, Duvic M, Ahmed S, Jain P, Fayad L. Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin. International journal of radiation oncology, biology, physics 111(3):e301, 2021. PMID: None.
22. Herrera AF, Zain J, Savage KJ, Feldman TA, Brammer JE, Chen L, Popplewell LL, Budde LE, Mei M, Leslie LA, Nair R, Iyer S. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas. Blood 138(None):133, 2021. PMID: None.
23. Mohamed, Parrish, Khan, Premji, Elias, Malpica. Prognostic Role of CD30 From a Retrospective Review of 295 Patients with Angioimmunoblastic T-Cell Lymphoma. TCL 309(21):S414, 2021. PMID: None.
24. Ahmed S, Strati P, Fayad L, Hagemeister F, Lee H J, Iyer S P, Nair R, Parmar S, Rodriguez A, Samaniego F, Steiner R, Wang M L, Pinnix C, Flowers C, Horowitz S, Claussen C, Johnson N, Mistry H, Adkins S, Shpall E J, Kebriaei P, Nieto Y, Hawkins M, Neelapu S S, Nastoupil L J, Westin J R. Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL). None None(None):None, 2021. PMID: None.
25. Nair R, Hadidi SA, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Fang P, Gunther JR, Jain P. Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. None 136(1):27-28, 2020. PMID: None.
26. Nair R, Pinnix C C, Gunther J R, Strati P, Westin J, Fayad L, Hagemeister F B, Iyer S P, Nastoupil L J, Parmar S, Rodriguez A, Steiner R, Dabaja B S, Fang P, Flowers C, Noorani M, Feng L, Neelapu S S, Ahmed S, Lee H J. MD Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma. ASCO None(None):None, 2020. PMID: None.
27. Ahmed S, Furquan F, Straiti P, Westin J, Fayad L, Hagemeister F B, Lee H J, Iyer S P, Nair R, Nastoupil L J, Parmar S, Rodriguez M A, Samaniego F, Steiner R, Wang M, Pinnix C C, Flowers C, Horowitz S B, Hawkins M, Neelapu S S. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). ASCO None(None):None, 2020. PMID: None.
28. Steiner R, Cramer F M, Singh P, Becnel M, Alcedo P E, Chin C K, Cuglievan B, Strati P, Ahmed S, Samniego F, Nair R, Gunther J R, Pinnix C C, Fang P, Dabaja B S, Feng L, Lee H J. Brentuximab vedotin with chemotherapy for advanced stage untreated classic Hodgkin’s lymphoma in a real-world setting. ASCO None(None):None, 2020. PMID: None.
29. Strati P, Furqan F, Westin J, Fayad L, Ahmed S, Lee H J, Iyer S P, Nair R, Nastoupil L J, Parmar S, Rodriguez M A, Samaniego F, Steiner R, Wang M, Pinnix C C, Flowers C, Horowitz S B, Hawkins M, Neelapu S S. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). ASCO None(None):None, 2020. PMID: None.
30. Hadidi SA, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS. Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood None(None):None, 2020. PMID: None.
31. JR Westin JR, L Nastoupil L, L Fayad L, F Hagemeister F, K Young K, T McDonnell T, S Neelapu S, RE Davis RE, M Green M, S Ahmed S, R Nair R, R Steiner R, H Lee H, M Rodriguez M, S Parmar S, H Chuang H. VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY. ICML None(None):None, 2019. PMID: None.
32. Westin J, Nastoupil L J, Fayad L, Hagemeister F B, Oki Y, Turturro F, Ahmed S, Rodriguez M A, Lee H J, Steiner R, Nair R, Parmar S, Young K H, McDonnell T, Chuang H, Green M R, Neelapu S S, Davis R E. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. ASCO None(None):None, 2019. PMID: None.
33. Anand K, Burns E, Sano D, Pingali S R, Westin J, Nastoupil L J, Lee H J, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner R, Nair R, Ahmed S, Fowler N H, Neelapu S S, Iyer S P. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. None None(None):None, 2019. PMID: None.
34. Tabchi S, Nair R, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash M H, Weber, Orlowski R Z, Alexanian R, Feng L, Manasanch E E. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology 30(15):8044, 2018. PMID: None.
35. Sano D, Nastoupil L J, Fowler N H, Fayad L, Hagemeister F B, Lee H J, Samaniego F, Wang M, Rodriguez M A, Iyer S P, Parmar S, Steiner R, Nair R, Adkins S, Arafat S, Rao A, Vallejo L, Hawkins M, Chen Y, Westin J R, Neelapu S S. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma. ASH None(None):None, 2018. PMID: None.
36. Nair R, Shah U, Kincaid H, Macfarlen J, Friedman E. Retrospective analysis of neoadjuvant chemoradiotherapy with carboplatin/ paclitaxel versus FOLFOX in newly diagnosed esophageal or junctional cancers: A single institution experience. Clinical Oncology 35(4):None, 2017. PMID: None.
37. S Adediran S, E Friedman E, R Nair R. Primary Pulmonary Carcinoid Tumors: A Single Institution Retrospective Review. Thoracic Oncology 12(11):S1574-S1575, 2017. PMID: None.
38. Nair R, Agostino N M, Shah U. Peritoneal lymphomatosis: When Occam's razor fail. None None(None):None, 2016. PMID: None.
39. Mayo R, Nair R, Gheith S. An Unusual Case of IgG4 Associated Marginal Zone B-cell Lymphoma Presenting as Subcutaneous Nodules Mimicking Lipomas. Pennsylvania Society of Oncology and Hematology None(None):None, 2016. PMID: None.
40. Nair R, Smith S J. Adrenal incidentaloma in young – Is it a gray Zone?. None None(None):None, 2016. PMID: None.
41. Sreedhar, Nair. A Case Report of Ruxolitinib Induced Hypocalcemia: A Stochastic or Deterministic Effect?. LVHN Scholarly Works None(None):None, 2016. PMID: None.
42. Nair, Gheith. A case report of an aggressive mantle cell lymphoma masquerading as chronic lymphocytic leukemia with catastrophic treatment complications. None None(None):None, 2016. PMID: None.
43. Sreedhar, Nair. A Case Report of Enteric Duplication Cyst: A Unique Presentation with Multiple Rare Associations. None None(None):None, 2015. PMID: None.
44. Davis, Nair, R Agostino R. Acute pancreatitis associated with TTP; A cause or effect. None None(None):None, 2015. PMID: None.
45. Hickey P, Nair R, Brodsky J, Shah H, Loven V. Undifferentiated Carcinoma withOsteoclast-Like Giant Cells of the Pancreatic Tail. Gastroenterology 148(4):S-939, 2015. PMID: None.
46. Patak, Nair. A Rare Cutaneous Harbinger of Acute Leukemia: A Case Report. ACP None(None):None, 2015. PMID: None.
47. HeiselA, Sreedhar A, Lamparella N, Nair, Gheith SM. Microlymphoma, A Rare Clinicopathologic Entity During the Evolution of an Aggressive Lymphoma: A Case Report. ACP None(None):None, 2015. PMID: None.
48. Sreedhar, Nair. A Very Rare Etiology of Deep Vein Thrombosis- ‘KILT Syndrome’. None None(None):None, 2015. PMID: None.
49. Tseytlin D, Bloomfield C, Nair R, Casey C, Valtsis V, Bucciarelli M, Kern C, Awuor S, Shreedhar A, Julia R. Improving Outcomes In Diabetic Patients. LVHN Scholarly works None(None):None, 2014. PMID: None.
50. Mastoris, Nair. A Potentially Fatal Etiology Of A Lumbar Radiculopathy. LVHN scholarly works None(None):None, 2014. PMID: None.
51. Nair, Ali, Bloomfield. Lymphoma Masquerading as Pneumonia with Acute Renal Failure: A rare clinical and radiological presentation of diffuse large B cell gastric lymphoma (DLBCL). None None(None):None, 2014. PMID: None.
52. Frankhouser S, Nair R. Continuity of care at the Lehigh valley physicians practice resident clinic. LVHN scholarly works None(None):None, 2013. PMID: None.

Book Chapters

1. Nair R, Vega F, Iyer S. Nodal Peripheral T cell Lymphoma. In: The MD Anderson Manual of Medical Oncology. 4. MCGraw Hill, LLC, 2022.
2. Nair R, Westin J. CAR T cells. In: Immunotherapy. Advances in Experimental Medicine and Biology. None. Springer, Cham, 297-317, 2021.
3. Nair, R, Westin, JR. CAR T Cells. In: Immunotherapy, 297-317, 2021.
4. Nair, R, Patel, K. What the Intensivists Need to Know About Critically Ill Myeloma Patients. In: Oncologic Critical Care, 1513-1530, 2019.
5. Nair, R, Patel, K. What the intensivists need to know about critically ill Lymphoma patients, 1499-1512, 2019.

Letters to the Editor

1. Lionel, AC, Gurumurthi, A, Fetooh, A, Eldaya, R, Ahmed, S, Iyer, SP, Nastoupil, L, Westin, JR, Nair, R, Fayad, LE, Malpica Castillo, LE, Tummala, S, Flowers, CR, Neelapu, SS, Wang, ML, Jain, P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leukemia and Lymphoma 65: 669-673, 2024.
2. Mamlouk, O, Strati, P, Feng, L, Sun, R, Ayers, AA, Steiner, RE, Nair, R, Flowers, CR, Ramdial, JL, Saini, N, Srour, S, Champlin, RE, Kebriaei, P, Nastoupil, L, Rodriguez, MA, Shpall, E, Nieto, Y, Westin, JR, Neelapu, SS, Mandayam, S, Ahmed, S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. British Journal of Haematology 204: e11-e16, 2024.